Seven weeks after scuttling its proposed initial public offering, Argos Therapeutics Inc. has raised a $25 million round of private capital to support ongoing development of its dendritic cell treatment for metastatic renal cell carcinoma.
Cash-strapped for months, Argos sought funds to begin a pivotal Phase III trial on AGS-003, a personalized treatment in which...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?